Table 2 Selected data of copanlisib monotherapy in relapsed or refractory B-cell-lymphoma subtypes in clinical trials
Trial | Subtype of lymphoma (%) | Number of patients | OR (%) | CR (%) | summary of treatment-emergent ≥ grade 3 (%) occurring in ≥10% of the total population |
|---|---|---|---|---|---|
Phase I [18] | FL (66.6), DLBCL (33.3) | 9 | 78% | 11% | hyperglycemia (33), hypertension (33), lung infection (22), neutropenia (11), rash (11), anemia (11) |
Phase II [20] | DLBCL (100) | 79 | 19.4 | 5 | hyperglycemia (33), hypertension (31) |
Phase II [21] | FL (73), MZL (16), SLL 8 (6), LPL/WM (4), DLBCL (1) | 142 | 59 (overall cohort), 70 (only MZL) | 12 (overall cohort), 9 (only MZL) | hyperglycemia (41), hypertension (24), lung infection (15), neutropenia (24) |